Royalty Report: Drugs, Cancer, Diagnostic – Collection: 4420


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Diagnostic
  • Biotechnology
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4420

License Grant
The Licensor entered into a development and marketing Agreement with licensee for the development and marketing of diagnostic, prognostic, or bio-analytical products.
License Property
Licensor has licensed the rights to develop Id based prognostics and diagnostics to Licensee in exchange for milestones, royalties and the right to use internally, any developed technology (such as new assays or monoclonal antibodies). The Licensor supports the laboratory work at Licensee by providing assays, reagents, tumor tissue and blood, as well as serving as consultants to provide current knowledge and expertise regarding new research findings in the field of Id proteins.

Licensor is a development stage biopharmaceutical company founded to create products that are uniquely useful for the treatment, diagnosis and prognosis of cancer.

Field of Use
Licensee is developing monoclonal antibodies (mAbs) for all four Id proteins (Id1, Id2, Id3 and Id4) for use in standard ELISA type tests and for kits for detection of the proteins in tumors and other tissues. These mAbs are critical to the development of diagnostics and all other research in the Id area. mAbs have been developed for Id1,  Id2, and Id3 and are being used for these purposes.

IPSCIO Record ID: 26530

License Grant
The Company signed a license agreement with the University for the exclusive rights of Mammastatin technology.
License Property
Mammastatin is a protein that has been found to be present in relatively higher levels in the breast tissue of healthy women as compared to those women that eventually have developed breast cancer.
Field of Use
The Comany developed the MSA test as a simple blood serum diagnostic that could measure the quantity of Mammastatin in blood serum using monoclonal antibody technology, whereby the results from that test could then be used to assess women’s risk of developing breast cancer.

IPSCIO Record ID: 27967

License Grant
Licensor, is willing to grant to the sublicensee a worldwide, nonexclusive, royalty-bearing sublicense to use such patent rights for the development and commercialization of Diagnostic Services, Licensed Reagents and Kits.  Certain patent rights including but not limited to screening, diagnosis, prognosis and monitoring tests, for the purpose of detecting changes associated with colorectal cancer, were licensed under the agreement dated as of February 5, 1992.
License Property
Diagnostic Service(s) shall mean the performance of laboratory-based assays covered in whole or in part by a Valid Claim of the Patent Rights.

U.S. Patent No. 5,352,775 & U.S.  Patent Application No.  08/861,910

Field of Use
Field shall mean the determination, in stool or samples prepared from stool, of the presence of, absence of or variation(s) within a nucleic acid of interest, or differences between a nucleic acid of interest and a reference standard or sample, including but not limited to screening, diagnosis, prognosis and monitoring tests, for the purpose of detecting changes associated with colorectal cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.